Diebold Nixdorf Inc (DBD) Stock Analysis
Verdict: HOLD
Aggressive deleveraging and software pivot offer significant valuation re-rating, provided the post-earnings technical breakdown stabilizes.
Investment score: 64/100
Analysis as of
Is Diebold Nixdorf Inc stock worth reviewing? The TradeMates thesis
Diebold Nixdorf is undervalued relative to its FCF generation and projected 2027 earnings, despite recent technical weakness.
7-factor investment score
- Valuation: 78/100 (weight 20%)
- Financial Health: 65/100 (weight 15%)
- Technical Momentum: 35/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 40/100 (weight 10%)
- Analyst Consensus: 85/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Diebold Nixdorf Inc opportunities and risks
What speaks for DBD
- Significant EPS Expansion Strategy
What speaks against DBD
- Persistent Insider Selling Liquidation
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| DBD | 23.7x | 0.6x | 9.7x | 26.1% | 2.9% | 9.0% |
| P | 113.5x | 6.5x | 60.8x | 70.2% | 5.7% | 2.0% |
| HPQ | 10.0x | 0.4x | 7.9x | 20.2% | 4.4% | 15.2% |
| SMCI | 13.6x | 0.5x | 13.5x | 8.4% | 3.7% | -37.3% |
| IONQ | 404.9x | 72.7x | 33.5x | 38.1% | 148.1% | -3.1% |
| GPGI | n/a | 0.0x | n/a | 0.0% | 0.0% | -2.0% |
| Peer median | 13.6x | 0.5x | 13.5x | 20.2% | 4.4% | -2.0% |
Frequently asked questions about Diebold Nixdorf Inc (DBD)
Is DBD stock a good investment?
The TradeMates model rates Diebold Nixdorf Inc as HOLD with an investment score of 64/100. Diebold Nixdorf is undervalued relative to its FCF generation and projected 2027 earnings, despite recent technical weakness. This is algorithmic model output, not personal investment advice.
Is DBD stock a buy?
The TradeMates model verdict for DBD is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.